Clinical Trial Update: A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) [Phase 3]

View source ↗

Summary

Phase 3 TRIDENT-3 trial comparing repotrectinib versus crizotinib in treatment-naïve ROS1-positive non-small cell lung cancer; the study is currently active but…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Crizotinib (crizotinib)
• Repotrectinib (repotrectinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: ACTIVE_NOT_RECRUITING